The 1982-1988 aspirin component of the Physicians' Health Study, a randomized trial of aspirin and β-carotene in primary prevention of cardiovascular disease and cancer among 22,071 US male physicians, was terminated early primarily because of a statistically extreme 44% reduction in first myocardial infarction, with inadequate precision and no apparent effect on the primary endpoint, cardiovascular death. Because of the demonstrated efficacy of aspirin in secondary prevention of cardiovascular death, nonfatal cardiovascular events may simultaneously be time-dependent confounders and intermediate variables. Aspirin use is strongly influenced by these as well as other diseases, side effects, and cardiovascular risk factors. The authors used a marginal structural model with time-dependent inverse probability weights to estimate the underlying causal effect of aspirin on cardiovascular mortality. Although intention-to-treat analyses found no effect (rate ratio = 1.00, 95% confidence interval (CI): 0.72, 1.38), the estimated causal rate ratio was altered to 0.75 but remained nonsignificant (95% CI: 0.48, 1.16). As-treated analyses suggested a more modest effect of aspirin use (rate ratio = 0.90, 95% CI: 0.65, 1.25). Although the numbers of cardiovascular deaths were insufficient to evaluate this endpoint definitively, use of such methods holds much potential for controlling time-varying confounders affected by previous exposure. Am J Epidemiol 2002;155:1045-53. 
FIGURE 1.
Directed acyclic graph of the hypothetical relation between aspirin use (ASA), cardiovascular (CV) death, and intervening cardiovascular events. Nonfatal cardiovascular events (e.g., myocardial infarction) are independent prognostic factors for cardiovascular death (A0). Additionally, they may be both predictors of subsequent aspirin use (A1) and predicted by past aspirin use (A2). k, current year; k -1, prior year.
observed aspirin use on cardiovascular death whether or not we control for intermediate nonfatal events. We used Robins' marginal structural model (8) (9) (10) to control for such timevarying confounders affected by previous exposure and estimated the causal effect of aspirin on cardiovascular death among the participants in the Physicians' Health Study.
MATERIALS AND METHODS

Marginal structural discrete-time survival model
The theory and form of the marginal structural model have been presented previously (8, 11, 12) , which we summarize here. Let t be a participant's time of death, with time measured in years since randomization. Let the random variable A(t) ϭ 1 if he took aspirin over the 12-month period prior to t and 0 otherwise, and let overbars represent exposure history, so that , for example, represents exposure history through t. Aspirin history could also be represented by more complex functions of exposure history. Let V be a random vector of time-independent baseline covariates measured before randomization.
In a time-dependent Cox model, the conditional hazard of cardiovascular death at time t as a function of recent aspirin use (as opposed to randomized aspirin assignment), A(t), and baseline covariates, V, is where β 1 and β 2 are unknown parameters and λ 0 is an unspecified baseline hazard. Since the effect of aspirin on cardiovascular risk is thought to be primarily acute and immediate, A(t) represents aspirin use in the past year only, and the parameter β 1 is a scalar. β 2 may be a vector of parameters. As discussed above, β 1 may not represent the underlying effect of interest in these as-treated models in the presence of time-varying confounders affected by previous treatment, such as nonfatal cardiovascular events.
To eliminate or reduce this bias from an analysis of observed exposure, we use inverse-probability-of-treatment 112 λ T 1t 0 A1t2, V2 ϭ λ 0 1t2exp1β 1 A1t2 ϩ β 2 V2, A1t2 weights (11, 13) . Let L(t) be a vector of time-dependent covariates, some of which may be time-dependent confounders as described above, with representing covariate history. To adjust for these covariates, we weight each subject's contribution to the risk set at time t by the "stabilized" time-dependent weight in which the product is taken over integer-years of study, and terms in the numerator and denominator represent the probability of aspirin use at time k given past exposure and baseline covariates, without and with also conditioning on the time-varying covariates , respectively. Since the weights themselves are unknown, we estimate them from the observed data by fitting a separate logistic regression model for the numerator and denominator. An alternative to the above weights are "nonstabilized" weights, W i (t), in which the numerator is replaced by 1, but such nonstabilized weights tend to be less efficient (11) .
To adjust for censoring by mortality from other causes or by termination of the aspirin arm of the study, a similar procedure is used to estimate inverse-probability-of-censoring weights, CW i (t). These weights are multiplied by the above weights to create an overall weight for each subject in each time period, SW i (t) ϭ AW i (t) × CW i (t).
We may then use pooled logistic regression (14) , weighted by SW i (t), to estimate the discrete-time survival model in the form where β 0 (t) may represent terms for the intercept and coefficients of time or functions of time, such as indicators, and β 1 represents the exposure effects of interest. Weighting each subject's contribution by SW i (t) creates a pseudopopulation in which the time-dependent covariates are not confounders but in which the causal effect of aspirin on cardiovascular mortality is the same. Thus, the observed exposure effect β 1 in the above model is an unbiased estimate of the log causal rate ratio, unconfounded by the time-varying covariates. This interpretation is true if all relevant time-dependent confounders are included in expression 2, called the assumption of no unmeasured confounders. If confounding still exists, whether unmeasured or inappropriately controlled, the causal interpretation will not hold. The above model may also be placed within the framework of counterfactual or potential outcomes models (11, 15, 16) , but doing so is not necessary for interpretation. For pedagogic purposes, we provide a simple example in the Appendix.
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The time-dependent weights SW i (t) induce a withinsubject correlation in the final model. Therefore, we used the ROBUST SAS software system macro to obtain robust, or empirical, variance estimates (17) . These robust estimates are equivalent to generalized estimating equation estimates (18) with an independent working covariance matrix but are generated more rapidly in large data sets than the generalized estimating equation estimates provided by the SAS software program GENMOD (17) . These robust variance estimates have been found to be conservative (i.e., larger than the true variance) (11) . Therefore, we also generated an estimate of the variance of our final hazard ratio by use of a simple nonparametric bootstrap procedure, estimating both the weights and rate ratios in 100 bootstrap samples (19) .
For comparison to the estimates derived from the marginal structural models, we also estimated the effects of aspirin from standard intention-to-treat and as-treated analyses. For comparability, we used pooled logistic regression in these analyses, both with and without the usual adjustment for time-varying covariates in time-dependent models.
Physicians' Health Study data
A description of the subjects and methods, as well as results of the intention-to-treat analysis of the randomized aspirin component of the Physicians' Health Study, have been published previously (1, 20) . Briefly, beginning in 1982, a 2 × 2 factorial design was used to randomize 22,071 US male physicians to 325 mg of aspirin every other day or placebo and 50 mg of β-carotene every other day or placebo. Eligible participants were aged 40-84 years and had no history of cardiovascular disease or cancer (21) . Every 6 months for the first year, then annually, participants were sent a supply of monthly calendar packs containing the study agents, with a brief questionnaire asking about their compliance with the treatment regimen as well as occurrence of any relevant events, including potential side effects. By the end of the aspirin phase of the study in January 1988, participants had been followed for an average of 60 months (range, 46-77 months), and mortality and morbidity information on the primary endpoints was virtually complete. The β-carotene component of the trial continued to its scheduled end in December 1995. The present analysis includes follow-up through the end of the aspirin component in 1988; however, since the final aspirin report was published in 1989, any remaining information regarding events occurring prior to termination of the aspirin arm of the study has been updated.
Observed aspirin use each year was computed from the compliance information provided on the annual questionnaires. Participants were asked about their use of the white pills containing either active aspirin or placebo as well as their use of nonstudy aspirin. This information was combined to estimate average aspirin use during the previous 12 months. In these analyses, the aspirin variable was classified as use for at least 90 days per year or use of at least half the study dose. At this level, some inhibition of platelet aggregation, and possible cardiovascular protection, would still be expected.
All reported study endpoints were reviewed by an endpoints committee of physicians, and only confirmed events were used in final analyses (1) . Confirmed cardiovascular mortality was the endpoint in these analyses. However, any reports of nonfatal cardiovascular events including MI, stroke, coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA), transient ischemic attack, and angina, and other reports of cardiovascular disease (such as artery surgery, intermittent claudication, pulmonary embolism, deep vein thrombosis, or atrial fibrillation), were considered as time-varying covariates whether confirmed later or not, since even those cardiovascular events that did not meet study criteria for confirmation could affect a participant's personal choice about using aspirin. Other predictors of aspirin use considered included randomized aspirin assignment; being unblinded to study treatment; known or suspected cardiovascular risk factors, such as age, body mass index, hypertension, family history of MI, smoking, exercise, consumption of alcohol, and use of multivitamins and vitamin E; potential side effects, including gastric symptoms and bleeding disorders, assessed as gastrointestinal bleeds, easy bruising, and other bleeds; and diagnosis of other diseases, including diabetes, cancer, chronic obstructive pulmonary disease, liver disease, and arthritis.
Reports of nonfatal events were accumulated and were carried forward over time, so that indicators, for example, of past nonfatal MI, represented ever having had the event.
Other risk factors were updated periodically throughout the study, and the last available information was carried forward, including over missing questionnaires. Because exposure and covariate information was assessed on annual questionnaires only, some consideration was given to the timing of events (22) . To predict aspirin use in a given year, only risk factors, side effects, and other diseases reported in prior years were included. However, because of the strong and immediate effect of nonfatal cardiovascular events on aspirin use, indicators for occurrence of such events in the current as well as prior years were included. In separate sensitivity analyses, we included only those cardiovascular events reported in prior years or used both current and prior reports for all predictors in models for aspirin use.
Pooled logistic regression analyses predicting aspirin use and censoring in each year were used to estimate the weights. For the numerator of AW i (t), models including previous aspirin use and time were used. For the denominator, all potential predictors of aspirin use described above were included in the logistic models. Lagged variables for previous aspirin use, nonfatal cardiovascular events, and possible side effects were also included. Because of strong interactions with both randomized aspirin assignment and previous use of aspirin, the probability of aspirin use was estimated separately within strata defined by these variables. We excluded the first year of observation from these analyses because of the lagging, particularly by previous aspirin use. Because 124 participants in a pilot study of the Physicians' Health Study, later randomized into the trial, received a slightly different set of questionnaires and schedule of risk factor information, these participants were excluded from current analyses. After elimination of deaths during the first year of follow-up (n ϭ 54) and participants for whom there was no follow-up compliance information (n ϭ 77), 21,816 participants remained for these analyses.
RESULTS
At baseline, participants were aged 54 years on average (±9.5 years), and 11 percent were current smokers (table 1) . There were no significant differences in baseline risk factors by randomized aspirin assignment (21) . Study compliance was high; 86 percent or more of the aspirin group reported using at least half the study dose throughout the follow-up period, and over 92 percent of the placebo group reported avoiding aspirin at this dose by the end of study.
By the end of the trial period, 441 participants reported an MI; in addition, 563 reported CABG or PTCA, 241 reported stroke, 344 reported transient ischemic attack, and 1,113 reported angina. While no formal analyses were conducted on these self-reported endpoints, some of which were disconfirmed later, fewer MIs occurred in the active group, consistent with the final trial results. There were 375 deaths in the years following the first, 146 of which (39 percent) were confirmed as cardiovascular deaths.
Use of aspirin was strongly associated with several factors, including intermediate nonfatal cardiovascular events, cardiovascular risk factors, purported side effects of aspirin, and other diseases. Predictors of aspirin use varied by both randomized assignment and by use of aspirin in the previous time period. Among those participants in the placebo group, predictors of starting aspirin use differed from those for continuing aspirin use once started (table 2) . Among those participants not using aspirin in the previous year, occurrence of nonfatal cardiovascular events was a strong predictor of the initiation of nonstudy aspirin use. Reporting an MI, CABG, PTCA, stroke, or transient ischemic attack in the current year (k) all greatly increased the probability of using aspirin during that time period, as expected. The effect of these nonfatal events on aspirin use diminished over time, as evidenced by a lower odds ratio for events occurring in prior years (k -1). Aspirin use was increased among those with cardiovascular risk factors, including smoking and family history of MI. Aspirin use or nonuse was also predicted by occurrence of other diseases considered but not by symptoms and side effects.
Among those in the placebo group who were already using aspirin in the prior year, nonfatal events were less predictive of continuing aspirin use (although they may have influenced initiation of aspirin use in the first place). Other risk factors, except for current smoking, were also less predictive in this group. This subset included 1,262 observations over time, representing 756 persons. The small number of participants in this group led to some difficulties in fitting the model. When separate indicators were used for MI and CABG/PTCA, for example, the weights became more variable. Therefore, we used the combined indicator for coronary artery disease.
Among those participants randomized to the active aspirin group (table 3) , predictors of use again differed by whether the participant had been using aspirin in the previous year (k -1). Among those who were using their assigned aspirin (ASA k -1 ϭ 1), those who experienced a stroke or "other" type of cardiovascular disease, as well as those who were unblinded to the study medication, were more likely to discontinue use. In addition, those who experienced symptoms or side effects of aspirin use or who developed another serious disease were more likely to stop. Those participants who were older, who exercised more, and who never smoked were more likely to continue to use active aspirin. Among those in the active group who had previously stopped using aspirin, there were fewer predictors of restarting aspirin use. These predictors included occurrence of "other" cardiovascular disease, hypertension, family history of MI, and occurrence of easy bruising, arthritis, and headache.
We also fit models for the probability of remaining uncensored by either death due to other causes or by the end of study to obtain estimates of the censoring weights CW i (t), which tended to be near 1. These analyses combined both randomized groups. The probability of censoring was less influenced by occurrence of nonfatal cardiovascular events but was higher given occurrence of other diseases, including cancer, chronic obstructive pulmonary disease, arthritis, and headache (data not shown). The probability of censoring was also higher among those participants who had hypertension, were older, had a higher body mass index, and exercised less.
In an intention-to-treat analysis, we found no effect of randomized aspirin assignment on cardiovascular mortality in this group (RR ϭ 1.00, 95 percent confidence interval (CI): 0.72, 1.38) (table 4), consistent with the published final results of the trial (1). This null finding remained after adjustment for intervening nonfatal events and cardiovascular risk factors using conventional time-varying covariates and also after adjustment for all predictors of aspirin use examined in 
* Subscript k denotes current year; subscript k Ϫ1 denotes any prior year. † ASA, aspirin use; MI, myocardial infarction; CABG, coronary artery bypass surgery; PTCA, percutaneous transluminal coronary angioplasty; TIA, transient ischemic attack; CVD, cardiovascular disease; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal.
‡ p values are based on robust standard errors. § Year 2 served as the reference in this subset since no one in the placebo group was assumed to be using aspirin at baseline. When we used weighted pooled logistic regression analysis to estimate the marginal structural model, the estimated causal effect of aspirin use was a larger reduction in cardiovascular mortality of 26 percent (RR ϭ 0.74, robust 95 percent CI: 0.48, 1.15). The p value obtained from the robust standard error was nonsignificant (p ϭ 0.18). Bootstrap replications led to similar estimates of the standard error. In sensitivity analyses concerning the timing of events, when Nonfatal cardiovascular events 
‡ p values are based on robust standard errors. § Year 2 served as the reference in this subset since everyone in the active aspirin group was assumed to be using aspirin at baseline.
we excluded current reports of nonfatal cardiovascular events, the strongest predictors of aspirin use, the estimated ratio was less extreme (RR ϭ 0.86, 95 percent CI: 0.58, 1.27) . This model may not control adequately for confounding by these cardiovascular events. When terms using current reports for all predictors were included, the rate ratio was reduced to 0.72 (95 percent CI: 0.44, 1.15).
DISCUSSION
In these data from the Physicians' Health Study, we found differences in results from analyses in which intention-totreat, as-treated, and marginal structural models were used. The intention-to-treat model produced null results for cardiovascular mortality, regardless of adjustment for intervening events or cardiovascular risk factors. However, intention-totreat analyses may be biased toward the null value in the presence of noncompliance, particularly by aspirin use among those who suffer an intervening nonfatal cardiovascular event. In this cohort of physicians, fewer than 10 percent of MIs and 7 percent of strokes were fatal (1), and over 85 percent of those who suffered a nonfatal MI subsequently used aspirin (2) . MI and other nonfatal cardiovascular events thus serve as time-dependent confounders that are affected by previous treatment. As such, standard analyses fail to correctly account for these variables.
A similar problem occurs in the as-treated analysis. Since MI and other intervening nonfatal events are intermediate variables in the causal pathway to cardiovascular mortality, controlling for them by using the usual methods is not appropriate. In these data, the as-treated analysis led to a nonsignificant estimated reduction in risk of 10 percent, or 14 percent after adjustment for cardiovascular risk factors. After adjustment for all other predictors of aspirin use, the estimated reduction increased to 19 percent.
The marginal structural model attempts to adjust for intervening events by applying time-varying inverse-probabilityof-treatment weights. This method weights the data to form a pseudopopulation in which these intermediate events are no longer associated with future exposure. The marginal structural model thus estimates the net or total effect of aspirin use versus nonuse including intervening pathways through nonfatal cardiovascular events. Use of this model led to an estimated 26 percent reduction in cardiovascular mortality with aspirin use, an effect larger than that estimated from either the intention-to-treat or as-treated analysis. Such an increased beneficial treatment effect often occurs in studies controlling for confounding by indication (23, 24) .
Note that the marginal structural model and the intentionto-treat analyses essentially estimate different contrasts, both of which are valid comparisons. If it were true that everyone who experienced an MI was subsequently treated with aspirin, under perfect compliance, the intention-to-treat analysis would compare cardiovascular mortality among those who use aspirin both before and after an MI with that among those who do not use aspirin until they experience an MI but then use aspirin for secondary prevention. This is also a valid clinical question, and, to the extent that MI is subsequently treated with aspirin, particularly in the placebo group, this is the question addressed by the intention-to-treat analysis. This comparison indicates little overall difference in cardiovascular mortality but, of course, a significant reduction in nonfatal MI with aspirin use. In contrast, the marginal structural model analysis attempts to answer the question of whether aspirin would be associated with cardiovascular death if intervening MI did not influence subsequent aspirin use.
The marginal structural model has limitations, however. Foremost is the fact that it makes the strong assumption of no unmeasured confounders. Estimated parameters from the marginal structural model can be used to estimate causal effects only if all relevant covariates are measured in the data and are controlled adequately in the analysis, including having appropriate and inclusive models for predicting exposure to construct the stabilized weights. Methods that do not make this assumption are available (25) , but they may have less power to detect treatment effects. The marginal structural model can correctly adjust for measured time-varying confounders that are affected by exposure, which is not true of standard methods such as regression or stratification.
These types of "causal" models, particularly those using population weighting schemes, hold much potential for further analyses of both randomized trial and observational data. They have been developed to adjust for censoring and compliance by using inverse probability of censoring weights (26) as well as analyses of time-varying confounders, as presented here. Alternative procedures include G-estimation (27, 28) and the G-computation algorithm (29) . As the technical details and methods of fitting are developed further, these models are likely to prove very useful in data analysis and interpretation, including in secondary analyses of randomized trials. Although such models can never replace well-designed and carefully conducted randomized trials, they can serve as an adjunct method and provide additional information or elucidate mechanisms. In many situations, they can estimate effects that cannot be studied through randomization for ethical reasons. As such, models such as these may soon hold an important place in the toolbox of quantitative epidemiologic methods. 
APPENDIX
To illustrate the marginal structural model, we generated a simple hypothetical example. Suppose that, as in the Physicians' Health Study, participants are randomized to aspirin or placebo use, with an outcome of death due to MI over 2 years, with annual assessments of exposure and outcome (appendix figure 1) . For simplicity, we assume that there is no other competing cause of death. During the first year, persons may experience an MI. Those who survive may either continue their randomized assignment or switch to the other exposure.
Probabilities were assigned to events at each point. Among those persons on placebo, the probability of MI in 1 year was set to 1 percent, with an immediate fatality rate of 20 percent (whether or not a person was using aspirin). Following an MI in year 1, the chance of death due to MI in year 2 was set to 20 percent among those not using aspirin. We also assumed that among those with no prior MI, the effect of aspirin on MI and MI death in a single year was to reduce risk by 50 percent, and, that among those who experienced a nonfatal MI in year 1, aspirin also reduced the risk of MI death in year 2 by 50 percent. Aspirin's direct effect was assumed to be immediate, with no lasting effect of prior use. Thus, the rate ratio for current aspirin use on MI in both primary and secondary prevention was assumed to be 0.5.
Compliance in year 1 was assumed to be perfect and, among those with no MI in year 1, was set to 95 percent in year 2 in each randomized group. After an MI occurred, the chance of a person using aspirin in year 2 was set to 80 percent, regardless of randomized assignment. Multiplying these probabilities in a population of 200,000 randomized
